Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− mice

Adeno-associated virus (AAV) is the most widely utilized vector for gene therapy. Proprotein convertase subtilisin/kexin type 9 (PCSK9), predominantly expressed in the liver, plays a crucial role in lipid regulation and atherosclerosis progression. Here, we developed a novel chimeric AAV8.P-PCSK9 sh...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaocui Chen, Minghui Sun, Xiang Ma, Yitong Ma, Bangdang Chen
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Molecular Therapy: Methods & Clinical Development
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050124002067
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832595769286197248
author Xiaocui Chen
Minghui Sun
Xiang Ma
Yitong Ma
Bangdang Chen
author_facet Xiaocui Chen
Minghui Sun
Xiang Ma
Yitong Ma
Bangdang Chen
author_sort Xiaocui Chen
collection DOAJ
description Adeno-associated virus (AAV) is the most widely utilized vector for gene therapy. Proprotein convertase subtilisin/kexin type 9 (PCSK9), predominantly expressed in the liver, plays a crucial role in lipid regulation and atherosclerosis progression. Here, we developed a novel chimeric AAV8.P-PCSK9 short hairpin RNA (shRNA) vector that incorporates a cross-species specific shRNA targeting PCSK9 to assess its effects on lipid levels and atherosclerosis in mice. AAV8.P demonstrated superior transduction efficiency and safety, achieving about 90% liver transduction and maintaining transgene expression for up to a year. The AAV8.P-PCSK9 shRNA exhibited typical liver-tropism and effectively silenced hepatic PCSK9. Moreover, it significantly lowered serum cholesterol and triglyceride levels while increasing LDL-R level without causing hepatotoxicity in wild-type mice. Additionally, it decreased PCSK9 expression and elevated low-density lipoprotein receptor expression in Apolipoprotein E-deficient mice, leading to early changes in lipid profiles but lacking a sustained impact on circulating lipids. Importantly, silencing PCSK9 resulted in reduced plaque areas with enhanced stability, decreased inflammatory macrophage infiltration, and lower levels of vascular and systemic inflammatory markers. These findings indicate that targeted silencing of hepatic PCSK9 significantly reduces lipid levels and effectively mitigates atherosclerosis progression by inhibiting inflammatory responses via the AAV8.P-PCSK9 shRNA vector, thereby providing critical support for its clinical translation.
format Article
id doaj-art-83b948de9646418fbf4b3a3da6f96c8e
institution Kabale University
issn 2329-0501
language English
publishDate 2025-03-01
publisher Elsevier
record_format Article
series Molecular Therapy: Methods & Clinical Development
spelling doaj-art-83b948de9646418fbf4b3a3da6f96c8e2025-01-18T05:04:46ZengElsevierMolecular Therapy: Methods & Clinical Development2329-05012025-03-01331101390Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− miceXiaocui Chen0Minghui Sun1Xiang Ma2Yitong Ma3Bangdang Chen4Xinjiang Key Laboratory of Cardiovascular Disease Research, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, P.R. China; Basic Medical College, Xinjiang Medical University, Urumqi 830011, P.R. ChinaDepartment of Nephrology, Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, P.R. ChinaXinjiang Key Laboratory of Cardiovascular Disease Research, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, P.R. China; Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, P.R. ChinaXinjiang Key Laboratory of Cardiovascular Disease Research, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, P.R. China; Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, P.R. ChinaXinjiang Key Laboratory of Cardiovascular Disease Research, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, P.R. China; Basic Medical College, Xinjiang Medical University, Urumqi 830011, P.R. China; Corresponding author: Bangdang Chen, Clinical Medical Research Institute of Xinjiang Medical University, 137 Liyushan South Road, Urumqi 830054, P.R. China.Adeno-associated virus (AAV) is the most widely utilized vector for gene therapy. Proprotein convertase subtilisin/kexin type 9 (PCSK9), predominantly expressed in the liver, plays a crucial role in lipid regulation and atherosclerosis progression. Here, we developed a novel chimeric AAV8.P-PCSK9 short hairpin RNA (shRNA) vector that incorporates a cross-species specific shRNA targeting PCSK9 to assess its effects on lipid levels and atherosclerosis in mice. AAV8.P demonstrated superior transduction efficiency and safety, achieving about 90% liver transduction and maintaining transgene expression for up to a year. The AAV8.P-PCSK9 shRNA exhibited typical liver-tropism and effectively silenced hepatic PCSK9. Moreover, it significantly lowered serum cholesterol and triglyceride levels while increasing LDL-R level without causing hepatotoxicity in wild-type mice. Additionally, it decreased PCSK9 expression and elevated low-density lipoprotein receptor expression in Apolipoprotein E-deficient mice, leading to early changes in lipid profiles but lacking a sustained impact on circulating lipids. Importantly, silencing PCSK9 resulted in reduced plaque areas with enhanced stability, decreased inflammatory macrophage infiltration, and lower levels of vascular and systemic inflammatory markers. These findings indicate that targeted silencing of hepatic PCSK9 significantly reduces lipid levels and effectively mitigates atherosclerosis progression by inhibiting inflammatory responses via the AAV8.P-PCSK9 shRNA vector, thereby providing critical support for its clinical translation.http://www.sciencedirect.com/science/article/pii/S2329050124002067proprotein convertase subtilisin/kexin type 9adeno-associated virusgene therapyatherosclerosisinflammation
spellingShingle Xiaocui Chen
Minghui Sun
Xiang Ma
Yitong Ma
Bangdang Chen
Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− mice
Molecular Therapy: Methods & Clinical Development
proprotein convertase subtilisin/kexin type 9
adeno-associated virus
gene therapy
atherosclerosis
inflammation
title Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− mice
title_full Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− mice
title_fullStr Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− mice
title_full_unstemmed Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− mice
title_short Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− mice
title_sort silencing hepatic pcsk9 via novel chimeric aav8 mitigates the progression of atherosclerosis by inhibiting inflammation in apoe mice
topic proprotein convertase subtilisin/kexin type 9
adeno-associated virus
gene therapy
atherosclerosis
inflammation
url http://www.sciencedirect.com/science/article/pii/S2329050124002067
work_keys_str_mv AT xiaocuichen silencinghepaticpcsk9vianovelchimericaav8mitigatestheprogressionofatherosclerosisbyinhibitinginflammationinapoemice
AT minghuisun silencinghepaticpcsk9vianovelchimericaav8mitigatestheprogressionofatherosclerosisbyinhibitinginflammationinapoemice
AT xiangma silencinghepaticpcsk9vianovelchimericaav8mitigatestheprogressionofatherosclerosisbyinhibitinginflammationinapoemice
AT yitongma silencinghepaticpcsk9vianovelchimericaav8mitigatestheprogressionofatherosclerosisbyinhibitinginflammationinapoemice
AT bangdangchen silencinghepaticpcsk9vianovelchimericaav8mitigatestheprogressionofatherosclerosisbyinhibitinginflammationinapoemice